NEW YORK – Delve Bio said Wednesday that it has inked a partnership with Broad Clinical Labs to improve access to metagenomic sequencing for patients with neurological infections.
Financial terms of the deal were not disclosed.
Through the partnership, Delve Bio said it will gain access to the "expertise, scalability, and efficiency" in metagenomic sequencing from Broad Clinical Labs, a subsidiary of the Broad Institute of MIT and Harvard. This will accelerate the company’s commercialization efforts of its metagenomic next-generation sequencing platform, including clinical operations that deliver results in two days.
"Delve Bio is working to bring infectious disease diagnostics into the genomics era, enabling patients with undiagnosed neurological infections to get a definitive diagnosis quickly," Delve Bio CEO Brad Murray said in a statement. "We’re proud to partner with Broad Clinical Labs to bring high-quality laboratory operations and sequencing at scale to Delve's customers."
Based in San Francisco, Delve Bio is commercializing a metagenomic test developed by University of California, San Francisco researchers to detect pathogen DNA and RNA in cerebrospinal fluid to help solve cases of meningitis and encephalitis. The company said its flagship assay, Delve Detect, is expected to become more broadly available this fall.